Difference between revisions of "Biotech Growth Rate outperforming classical pharmaceuticals"
| Line 3: | Line 3: | ||
==Enablers:== | ==Enablers:== | ||
• Hope for good profit margins | • Hope for good profit margins<br> | ||
• Hope for huge ROE | • Hope for huge ROE<br> | ||
• Potential for spectacular breakthroughs in Research. | • Potential for spectacular breakthroughs in Research. | ||
<br> | <br> | ||
Revision as of 13:03, 2 December 2005
Description:
Over the last years, the growth rate of biotech industry has by far outperformed the one of the classical pharma industry. This has not had a positive impact on the profitability of biotech as such – profitability of most classical pharma majors is still higher than the one of most biotech companies – but it has shown in the development of stock prices. Biotechnology stocks have outperformed the ones of classical pharma majors thanks to the hope for future profits.
Enablers:
• Hope for good profit margins
• Hope for huge ROE
• Potential for spectacular breakthroughs in Research.
Inhibitors:
• Increase (instead of decrease) of R&D cost in biotechnology • Decrease in R&D costs for classical crugs • Entry barriers getting lower because of increased availability of fundamental research • Drug Approval regulations getting stricter • Insecurity regarding the development of legal frameworks • Price Pressure due to exploding healthcare cost
Paradigms:
• Investors look elsewhere
Experts:
See our Research regarding Growth and Development issues
Timing:
Web Resources:
See our Research regarding Growth and Development issues